drugset / Trial / NCT02662556

A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain

NCT02662556

Phase 3 Completed 140 enrolled Talphera, Inc
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label study in patients 40 years and older who are undergoing a surgical procedure. Patients may receive one dose of ST 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.

Timeline

Start
2016-03
Primary completion
2016-06
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Sufentanil Other / unclassified 30 ug Other

Indications

No indication recorded.